Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

New Ultrasound Applications Detects Early Response to Pancreatic Cancer Therapy

By Medimaging International staff writers
Posted on 06 Mar 2013
Print article
Image: 3-D Ultrasound Molecular Imaging (USMI) images of nonresponder and responder pancreatic xenografts before (day 0) and after (day 2) treatment. The grayscale image shows a volume of the tumor and surrounding tissue. The green region is the molecular signal (Photo courtesy of the University of North Carolina).
Image: 3-D Ultrasound Molecular Imaging (USMI) images of nonresponder and responder pancreatic xenografts before (day 0) and after (day 2) treatment. The grayscale image shows a volume of the tumor and surrounding tissue. The green region is the molecular signal (Photo courtesy of the University of North Carolina).
In a recent study, investigators utilized dynamic contrast enhanced-perfusion imaging (DCE-PI) and ultrasonic molecular imaging (USMI) to gauge response to therapy for pancreatic cancer.

The research was published in the January 2013 issue journal Technology in Cancer Research and Treatment. Paul Dayton, PhD, University of North Carolina (UNC) Lineberger Comprehensive Cancer Center (Chapel Hill, USA), and senior author of the study, said, “What we found is that using two noninvasive technologies, we can detect response to therapy earlier than by relying on tumor volume changes. Having new noninvasive, inexpensive technologies available to measure response to therapy earlier during the course of treatment would be a significant advance in the ability to tailor a person’s treatment to improve outcomes.”

Dr. Dayton, a UNC associate professor of biomedical engineering, worked with Jen Jen Yeh, M.D, an associate professor of surgery and pharmacology, to assess the imaging technologies on human pancreatic cancer in a preclinical model. Both investigators are members of the Lineberger Comprehensive Cancer Center.

USMI has the ability to depict noninvasively the biologic processes at the cellular and molecular levels. It accomplishes this with the use of targeted contrast agents, which are markers that bind to specific proteins expressed on cancer cells within the body. These contrast agents enable a conventional ultrasound system to identify signals from cancer cells that would otherwise be undetectable.

Ultrasound DCE-PI is a technique used noninvasively to track the blood flow in the microcirculation. Because growing tumors require abnormally increased blood flow, alterations in blood vessel structure or density can provide data regarding tumor malignancy. The researchers employed a drug that suppresses a protein specific to tumors. They then used the imaging applications to gauge the response of two different tumors, one known to respond to the drug therapy, and a second known not to respond. The findings indicated that USMI was able to detect molecular signs of tumor response to therapy after only two days.

A change in blood flow in the tumor was seen to detect response after day 14 using DCE-PI. Over the same period, standard volume measurements were not able to detect therapeutic response, and prior studies suggested that volume measurements do not become indicative of response until approximately 28 days. Therefore, these modalities revealed a substantial improvement in the early identification of tumor response to therapy, using contrast enhanced ultrasound imaging.

The contrast agents for USMI currently in clinical trials in Europe for cancer imaging, however, they are not yet available in the United States.

Related Links:
University of North Carolina Lineberger Comprehensive Cancer Center



Print article
Radcal

Channels

Radiography

view channel
Image: The Affirm prone biopsy system (Photo courtesy of Hologic).

Prone Biopsy System Offers 3D Imaging-Guided Breast Biopsy

A novel prone biopsy system allows radiologists to better target lesions found during three dimensional (3D) guided mammography exams, as well as other screening modalities. The Hologic Affirm Prone... Read more

Nuclear medicine

view channel
Image: MRV tracing in a mouse thalamus (Photo courtesy of the Salk Institute for Biological Studies).

New Reagent Helps Map Neural Connections in Brain

An improved rabies virus tracer visualizes neural circuitry in the brain, helping to understand more about motor diseases and neurodevelopmental disorders. Researchers at the Salk Institute for Biological... Read more

General/Advanced Imaging

view channel

Early Intervention with Stent Retrievers Improves Outcomes for Ischemic Stroke Patients

New research has shown that restoration of blood flow to the brain within two and a half hours from the onset of the first signs of acute ischemic stroke resulted in none, or only minimal disability in 91% of patients. Endovascular therapy in the early stages of the onset of stroke symptoms significantly improved functional... Read more

Imaging IT

view channel

World Medical VR Technology Company Unveils First-of-Its-Kind Neurosurgery Surgical Visualization Platform

A novel neurosurgery Virtual Reality (VR) visualization platform has been demonstrated at the NVIDIA GPU Technology Conference (GTC) 2016 in California (USA). The enterprise-wide solution is intended to help clinicians plan, prepare, and perform neurosurgery, and enable the surgeon to empower and engage their patients... Read more

Industry News

view channel
Image: Mazor Robotics\' Renaissance Image Guidance Robot in the Hand of a Surgeon (Photo courtesy of Mazor Robotics).

Medical Image Guidance Systems Developer Reports Demand for Systems in Q1 2016

The developer of an innovative guidance system that can improve the accuracy and clinical outcomes for spine and brain surgery procedures, has announced demand for its systems during the first quarter of 2016.... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.